Gilead Sciences edges higher to $125.14 as FDA approves new metastatic breast cancer therapy, Gilead Sciences

Traders Union
All News
Companies
Gilead Sciences up 0.07% today

Highlights

Gilead Sciences is under sustained bearish pressure, trading below significant short-, medium-, and long-term moving averages.
Momentum and oscillator signals remain negative overall, indicating sellers dominate and a weak trend persists.
Expected range for the coming week is $122.50 to $128.50, with less than 20% probability of an upward breakout.

Sustained downside pressure as price remains under key averages

Gilead Sciences (GILD) is trading at $125.14, below the MA-20 ($128.06), MA-50 ($131.16), and MA-200 ($129.52), signaling continued short-, medium-, and long-term pressure from sellers. The Ichimoku Kijun at $129.28 sits above the current price, acting as immediate resistance. Near-term support is found at the EMA-5 ($125.03), with key support at the MA-200 ($129.52). Immediate resistance is marked by the Ichimoku Kijun ($129.28), with key resistance at the MA-50 ($131.16).

Mixed momentum signals as bearish bias offsets recent rebound

Momentum signals are mostly negative on D1. MACD shows strong bearish momentum, and ADX indicates a weak trend. Oscillators diverge: RSI (42.53) and CCI (-56.88) both suggest bearish or oversold conditions, while Stoch RSI is overbought. BBP (0.46, direction: oversold) points to sellers dominating intraday price action. AO direction is neutral and does not reinforce the prevailing trend. This week, GILD has risen $1.38 (1.12%) from a previous close of $123.76, with the current price positioned in the upper part of the weekly range. Weekly volatility stands at 3.41%. The tone reflects a recovery from the weekly low and an approach toward resistance.

Downside risk prevails as weak momentum limits upside potential

For the coming week, the expected price range is $122.50 to $128.50, keeping the price well within the 52-week range of $105.79–$157.29. Probability of an upward move is very low (less than 20%), making a downside scenario more likely. The baseline scenario is for GILD to consolidate between support and resistance as momentum remains weak. A bullish breakout above $129.28 could open room toward $131, but would require a shift in momentum. A bearish scenario sees a break below $122.50, potentially testing lower supports, especially if weakness persists from technical indicators on both D1 and W1.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Gilead Sciences faced ongoing selling pressure and lacked momentum for a near-term recovery. Traders should closely monitor for signs of stabilization or renewed downside, as any significant break in the current price action could define the next directional move.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.